^
    Evidence Level:
    Resistant: A1 - Approval

    [NRAS exon 3 mutation-Colorectal Cancer-panitumumab]

    Source:
    FDA
    Test:

    Praxis Extended RAS Panel

    Excerpt:
    Vectibix is not indicated for the treatment of patients with colorectal cancer that harbor somatic RAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of either KRAS or NRAS and hereafter is referred to as “RAS.
    Evidence Level:
    Resistant: A1 - Approval

    [NRAS exon 4 mutation-Colorectal Cancer-panitumumab]

    Source:
    FDA
    Test:

    Praxis Extended RAS Panel

    Excerpt:
    Vectibix is not indicated for the treatment of patients with colorectal cancer that harbor somatic RAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of either KRAS or NRAS and hereafter is referred to as “RAS.